Back to Search
Start Over
Complete Pathologic Response After Concurrent Treatment with Pembrolizumab and Radiotherapy in Metastatic Colorectal Cancer: A Case Report
- Source :
- OncoTargets and therapy
- Publication Year :
- 2021
- Publisher :
- Dove, 2021.
-
Abstract
- Due to specific genetic characteristics, therapeutic options for colorectal cancer (CRC) with DNA mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) are limited. Although programmed death 1 (PD-1) blockade has been shown to be highly effective therapy for dMMR/MSI-H CRC, there is a need to develop new therapeutic paradigms to further improve survival rates of patients with dMMR/MSI-H CRC. So far, there is no case report on the use of immunotherapy combined with radiotherapy (RT) for the treatment of dMMR/MSI-H metastatic CRC (mCRC). Here, we report a 64-year-old patient diagnosed with mCRC who experienced a complete pathological response (pCR) after successfully conversion treatment with pembrolizumab and RT, and remains to be tumor-free during a follow-up of 11 months while off therapy. Immunohistochemical staining for MLH1, MSH2, MSH6, and PMS2 on the intestinal biopsy samples revealed loss of MLH1 and PMS2 protein expression. The present case report adds to the limited data on the safety and effectiveness of local RT combined with immunotherapy for patients with dMMR/MSI-H mCRC. This combination therapy appears to be a potential treatment for dMMR/MSI-H mCRC and deserves further exploration.
- Subjects :
- 0301 basic medicine
Oncology
medicine.medical_specialty
congenital, hereditary, and neonatal diseases and abnormalities
Combination therapy
Colorectal cancer
medicine.medical_treatment
Case Report
colorectal cancer
Pembrolizumab
MLH1
03 medical and health sciences
0302 clinical medicine
Internal medicine
PMS2
Medicine
Pharmacology (medical)
neoplasms
radiotherapy
business.industry
nutritional and metabolic diseases
medicine.disease
digestive system diseases
MSH6
Radiation therapy
030104 developmental biology
MSH2
030220 oncology & carcinogenesis
pathological complete response
immunotherapy
pembrolizumab
business
Subjects
Details
- Language :
- English
- ISSN :
- 11786930
- Volume :
- 14
- Database :
- OpenAIRE
- Journal :
- OncoTargets and therapy
- Accession number :
- edsair.doi.dedup.....5daf9de66f6d3e398ec55e3f8248f172